SMA Neurologists News and Resources
Neurology Info 1
Design settings and even apply custom CSS to this text in the module Advanced settings.
Neurology Info 2
Design settings and even apply custom CSS to this text in the module Advanced settings.
Neurology Info 3
Design settings and even apply custom CSS to this text in the module Advanced settings.
Featured Neurologists Articles on HCP
A Physical Therapist’s Perspective On a Treatment for SMA in Patients 2 Months and Older Sponsored Post
As key team members in the management of spinal muscular atrophy (SMA),1physical therapists need to understand how disease-modifying therapies may impact patients with SMA and how to best assess these patients over time. Evrysdi (risdiplam) is a disease-modifying...
Phase 3 Apitegromab Trial Planned for Non-ambulatory Types 2, 3
Scholar Rock plans to soon initiate a Phase 3 clinical trial of apitegromab, its investigational muscle-directed treatment for spinal muscular atrophy (SMA), in type 2 and 3 patients who are unable to walk. “We anticipate initiating a Phase 3 trial to evaluate...
A Physical Therapist’s Perspective On a Treatment for SMA in Patients 2 Months and Older Sponsored Post
As key team members in the management of spinal muscular atrophy (SMA),1physical therapists need to understand how disease-modifying therapies may impact patients with SMA and how to best assess these patients over time. Evrysdi (risdiplam) is a disease-modifying...
Neurofilament Blood Levels Likely to Predict Treatment Response in SMA
In infants with spinal muscular atrophy (SMA) type 1, lower blood levels of phosphorylated neurofilament heavy chain (pNF-H) — a marker of nerve cell damage — before starting treatment with Spinraza (nusinersen) are significantly associated with greater motor gains...
New Quality of Life Survey Aims to Help Inform SMA Community Needs
BioNews Insights is launching a new survey, in collaboration with SMA News Today, with the goal of understanding how different aspects of this disease affect an individual’s quality of life. The survey, which is expected to take about 15 minutes to complete,...
New Data-sharing Program Aims to Speed Innovation in Rare Diseases
A new U.S. initiative called Rare Disease Cures Accelerator–Data and Analytics Platform — dubbed RDCA–DAP — aims to accelerate treatment innovation across rare diseases by sharing existing patient data and promoting the standardization of new data collection. Launched...
Latest Posts from SMA News Today
Recent SMA Neurologist News
RSS feed from SMA News Today
SMA Forums -- Neurologist
RSS feed from SMA News Today
